Traders should monitor for future clinical updates on CAD-1005 in HIT and potential partnership announcements around its metabolic indications. While not immediately revenue-generative, the expanded mechanism could increase strategic interest given the large diabetes/obesity market, especially as an adjunct to GLP-1 therapies.
Price Chart
Executive Summary
Cadrenal Therapeutics released preclinical data showing its 12-LOX inhibitor, CAD-1005, may have therapeutic benefits in obesity and Type 2 diabetes by reducing inflammation and improving metabolic function. The findings expand the potential applications of CAD-1005 beyond its primary focus on heparin-induced thrombocytopenia (HIT), where it has already shown clinical promise and holds FDA Fast Track and Orphan Drug designations.
Key Facts
- Preclinical data show CAD-1005 improves glycemic control, reduces pancreatic β-cell loss, and lowers inflammation in adipose and pancreatic tissues.
- CAD-1005 is the only selective 12-LOX inhibitor in clinical development.
- The drug has received FDA Fast Track and Orphan Drug designations for HIT, as well as EMA orphan status.
- Phase 2 trial results in HIT showed a reduction in thrombotic events.
- Next-generation compound CAD-2000 is an orally bioavailable 12-LOX inhibitor in development for chronic conditions.
- Company's lead focus remains HIT; broader metabolic applications are exploratory and not yet in clinical trials.
Financial Impact
No immediate financial impact; potential long-term value expansion if 12-LOX inhibition proves viable in diabetes/obesity markets.
Risk Factors
- Preclinical data do not guarantee clinical success.
- No current trials in diabetes/obesity; therapeutic expansion remains speculative.
- Company is small-cap ($18M market cap) with high development and regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9298 (−4.37%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9298 (−46.87%) |
Jul 21, 2026 13w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9298 (−57.15%) |
Jul 21, 2026 13w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9298 (−57.15%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9298 (+74.17%) |
Jun 29, 2026 16w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9298 (−72.16%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9298 (−73.43%) |
Jun 15, 2026 18w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9298 (+69.41%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9298 (−84.55%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9298 (−86.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers